
  
    
      
        Background_NNP
        Atherosclerosis_NNP and_CC coronary_JJ heart_NN disease_NN (_( CHD_NNP )_) have_VBP
        long_RB been_VBN considered_VBN major_JJ contributors_NNS to_TO morbidity_NN and_CC
        mortality_NN in_IN developed_VBN countries_NNS [_NN 1_CD ,_, 2_CD ,_, 3_CD ]_NN ._. One_CD noted_VBD
        exception_NN is_VBZ the_DT low_JJ mortality_NN of_IN CHD_NNP in_IN France_NNP ,_,
        particularly_RB the_DT southwest_JJS region_NN [_NN 4_CD ,_, 5_CD ,_, 6_CD ]_NN ._. This_DT
        phenomenon_NN ,_, commonly_RB referred_VBD to_TO as_IN the_DT French_JJ paradox_NN ,_, may_MD
        be_VB associated_VBN with_IN high_JJ consumption_NN of_IN red_JJ wine_NN [_NN 7_CD ,_, 8_CD ]_NN ._. A_DT
        negative_JJ correlation_NN between_IN CHD_NNP and_CC alcohol_NN consumption_NN
        was_VBD first_RB noted_VBD 25_CD years_NNS ago_RB ,_, and_CC numerous_JJ studies_NNS since_IN
        have_VBP confirmed_VBN a_DT statistically_RB significant_JJ inverse_NN
        relationship_NN between_IN these_DT two_CD factors_NNS [_NN 9_CD ,_, 10_CD ,_, 11_CD ,_, 12_CD ,_, 13_CD ,_,
        14_CD ]_NN ._. 
        In_IN vivo_NN studies_NNS have_VBP shown_VBN that_DT wine_NN
        consumption_NN ,_, particularly_RB red_JJ wine_NN ,_, is_VBZ more_RBR effective_JJ in_IN
        the_DT prevention_NN of_IN CHD_NNP not_RB seen_VBN with_IN other_JJ forms_NNS of_IN
        alcoholic_JJ beverages_NNS [_NN 15_CD ,_, 16_CD ,_, 17_CD ]_NN ._. Accordingly_RB ,_, it_PRP has_VBZ been_VBN
        postulated_JJ that_IN naturally_RB occurring_VBG components_NNS in_IN wine_NN
        might_MD afford_VB or_CC contribute_VB to_TO its_PRP$ enhanced_JJ protection_NN
        against_IN CHD_NNP by_IN targeting_VBG sites_NNS that_WDT participate_VBP in_IN the_DT
        etiology_NN of_IN CHD_NNP ,_, including_VBG soluble_JJ blood_NN components_NNS (_( LDL_NNP )_) ,_,
        cellular_JJ blood_NN elements_NNS (_( platelets_NNS )_) ,_, or_CC the_DT vasculature_NN
        itself_PRP (_( endothelium_NN )_) ._. Siemann_NNP and_CC Creasy_NNP proposed_VBD that_IN
        trans-resveratrol_JJ ,_, a_DT tri-hydroxy_JJ stilbene_NN ,_, in_IN red_JJ wine_NN
        exhibits_VBZ cardioprotective_JJ properties_NNS [_NN 18_CD ]_NN and_CC can_MD inhibit_VB
        LDL_NNP oxidation_NN [_NN 19_CD ]_NN ,_, suppress_VB smooth_JJ muscle_NN proliferation_NN [_NN
        20_CD ]_NN ,_, induce_VB nitric_JJ oxide_NN synthase_NN expression_NN [_NN 21_CD ]_NN and_CC
        block_VB collagen-induced_JJ aggregation_NN responses_NNS in_IN washed_VBN
        platelets_NNS [_NN 22_CD ,_, 23_CD ,_, 24_CD ]_NN ._. However_RB ,_, relatively_RB few_JJ studies_NNS
        have_VBP been_VBN performed_VBN on_IN the_DT effects_NNS of_IN resveratrol_NN on_IN
        vascular_NN components_NNS such_JJ as_IN the_DT endothelial_NN cells_NNS ,_, which_WDT
        are_VBP known_VBN to_TO play_VB a_DT critical_JJ role_NN in_IN maintaining_VBG the_DT
        integrity_NN and_CC functioning_NN of_IN the_DT vascular_NN endothelium_NN ._.
        Homeostasis_NNP of_IN the_DT vascular_NN endothelium_NN ,_, both_DT with_IN respect_NN
        to_TO metabolic_JJ and_CC physiologic_JJ activities_NNS ,_, can_MD be_VB affected_VBN by_IN
        overall_JJ nutritional_JJ status_NN and_CC by_IN specific_JJ ingredients_NNS in_IN
        the_DT diet_NN [_NN 25_CD ,_, 26_CD ,_, 27_CD ]_NN ._.
        The_DT aims_NNS of_IN the_DT present_JJ study_NN were_VBD to_TO determine_VB changes_NNS
        resulting_VBG from_IN resveratrol_NN :_: endothelial_NN cell_NN interaction_NN ._. We_PRP
        observed_VBD that_DT resveratrol_NN induced_VBD significant_JJ cellular_JJ and_CC
        biochemical_JJ changes_NNS in_IN endothelial_NN cells_NNS ,_, which_WDT were_VBD
        accompanied_VBN by_IN altered_VBN functional_JJ responsiveness_NNS to_TO
        conditions_NNS simulating_VBG arterial_NN flow_NN ._. Since_IN previous_JJ studies_NNS
        have_VBP shown_VBN several_JJ signaling_VBG molecule_NN changes_NNS during_IN
        reorganization_NN of_IN the_DT endothelial_NN cell_NN cytoskeleton_NN
        accompanying_VBG arterial_NN shear_NN stress_NN [_NN 28_CD ,_, 29_CD ,_, 30_CD ,_, 31_CD ]_NN ,_, we_PRP
        evaluated_VBD the_DT same_JJ set_NN of_IN biochemical_JJ parameters_NNS in_IN
        resveratrol-treated_JJ cells_NNS ._. Use_NN of_IN selective_JJ signaling_VBG
        pathway_NN inhibitors_NNS allowed_VBD the_DT demonstration_NN that_IN the_DT
        cytoskeletal_NN changes_NNS elicited_JJ by_IN resveratrol_NN depended_VBD on_IN
        intracellular_NN calcium_NN and_CC tyrosine_NN kinase_NN activity_NN changes_NNS ,_,
        and_CC also_RB appeared_VBD to_TO be_VB linked_VBN to_TO integrity_NN of_IN actin_NN
        microfilaments_NNS and_CC microtubule_NN network_NN ._. Resveratrol_NNP
        treatment_NN also_RB led_VBD to_TO activation_NN of_IN ERK_NNP 1_CD /_NN 2_CD MAP_NNP kinase_NN ,_,
        similar_JJ to_TO changes_NNS induced_VBN by_IN shear_NN [_NN 30_CD ,_, 31_CD ]_NN ._. Thus_RB
        resveratrol_NN may_MD act_VB by_IN a_DT mechanism_NN (_( s_VBZ )_) closely_RB resembling_VBG
        that_WDT triggered_VBN by_IN shear_NN stress_NN ._.
      
      
        Results_NNS
        
          Resveratrol_NNP induces_VBZ morphologic_JJ change_NN in_IN
          endothelial_NN cells_NNS
          Sterilized_NNP plastic_NN 18_CD mm_NN ×_NN 21_CD mm_NN coverslips_NNS were_VBD
          seeded_VBN with_IN BPAEC_NNP and_CC treated_VBN 24_CD h_NN later_RB with_IN various_JJ
          concentrations_NNS of_IN resveratrol_NN ._. Following_VBG an_DT additional_JJ 2_CD
          day_NN of_IN culture_NN ,_, the_DT coverslips_NNS containing_VBG the_DT attached_VBN
          BPAECs_NNP were_VBD fixed_VBN ,_, stained_JJ with_IN rhodamine-phalloidin_JJ ,_, and_CC
          mounted_VBD onto_IN slides_NNS for_IN analysis_NN by_IN confocal_NN microscopy_NN ._.
          The_DT polyphenol_NN (_( 100_CD μM_NN )_) had_VBD a_DT distinct_JJ morphologic_JJ
          effect_NN ,_, changing_VBG the_DT cells_NNS from_IN a_DT boxy_JJ ,_, cobblestone-like_JJ
          appearance_NN (_( panel_NN A_DT ,_, Fig_NNP ._. 1_LS )_) to_TO an_DT elongated_JJ ,_, ellipsoidal_NN
          shape_NN with_IN long_JJ ,_, tortuous_JJ processes_VBZ (_( panel_NN B_NNP )_) ._. As_RB little_JJ
          as_IN 25_CD μM_NN resveratrol_NN sufficed_VBD to_TO induce_VB these_DT cellular_JJ
          changes_NNS ,_, in_IN passage_NN 4_CD -_: 7_CD cells_NNS (_( compare_VB panel_NN C_NNP with_IN panel_NN
          A_DT ,_, Fig_NNP ._. 2_LS )_) ._. To_TO quantify_VB the_DT percentages_NNS of_IN cells_NNS with_IN the_DT
          elongated_JJ morphology_NN ,_, a_DT minimum_NN of_IN 300_CD cells_NNS in_IN
          representative_NN microscopic_JJ field_NN were_VBD counted_VBN and_CC the_DT
          results_NNS presented_VBN in_IN Fig_NNP ._. 3_LS ._. The_DT percentage_NN of_IN cells_NNS
          showing_VBG the_DT elongated_JJ phenotype_NN is_VBZ proportional_JJ to_TO the_DT
          concentration_NN of_IN resveratrol_NN added_VBD to_TO the_DT culture_NN ._.
          Treatment_NNP with_IN resveratrol_NN also_RB suppressed_VBD growth_NN of_IN
          BPAEC_NNP (_( data_NNS not_RB shown_VBN )_) ,_, as_IN we_PRP previously_RB reported_VBD [_NN
          21_CD ]_NN ._.
        
        
          Resveratrol_NNP treatment_NN leads_VBZ to_TO increased_VBN adherence_NN
          of_IN BPAEC_NNP under_IN simulated_JJ arterial_NN flow_NN conditions_NNS
          To_TO test_VB whether_IN functional_JJ changes_NNS may_MD accompany_VB the_DT
          modified_VBN morphology_NN ,_, control_NN and_CC 2_CD day_NN and_CC 100_CD μM_NN
          resveratrol-treated_JJ cells_NNS were_VBD exposed_VBN to_TO 0_CD min_NN
          (_( control_NN )_) ,_, 2_CD min_NN ,_, or_CC 5_CD min_NN of_IN simulated_JJ arterial_NN shear_NN
          stress_NN using_VBG a_DT parallel_JJ plate_NN perfusion_NN chamber_NN (_( see_VB
          Materials_NNPS and_CC Methods_NNP )_) ._. Following_VBG the_DT shear_NN challenge_NN ,_,
          cells_NNS remaining_VBG attached_VBN were_VBD scored_VBN by_IN staining_VBG with_IN
          rhodamine-phalloidin_JJ ,_, as_IN described_VBN ._. Since_IN the_DT cells_NNS were_VBD
          evenly_RB distributed_VBN throughout_IN the_DT area_NN of_IN the_DT coverslip_NN
          exposed_VBN to_TO flow_VB ,_, representative_NN pictures_NNS were_VBD taken_VBN of_IN
          the_DT confocal_NN microscopy_NN fields_NNS located_VBN directly_RB in_IN the_DT
          center_NN of_IN the_DT coverslip_NN ,_, and_CC the_DT number_NN of_IN cells_NNS were_VBD
          counted_VBN ._. As_IN can_MD be_VB seen_VBN in_IN Fig_NNP ._. 4_LS ,_, compared_VBN to_TO the_DT 0_CD min_NN
          sample_NN ,_, a_DT significant_JJ percentage_NN of_IN resveratrol-treated_JJ
          BPAEC_NNP remained_VBD attached_VBN to_TO the_DT plastic_NN coverslips_NNS after_IN 2_CD
          min_NN and_CC 5_CD min_NN flow_NN challenge_NN ._. In_IN comparison_NN ,_, under_IN
          identical_JJ experimental_JJ conditions_NNS ,_, cells_NNS adhering_VBG to_TO the_DT
          coverslips_NNS decreased_VBD dramatically_RB in_IN controls_NNS ,_, with_IN
          virtually_RB no_DT cells_NNS remaining_VBG after_IN a_DT 5_CD min_NN simulated_JJ
          flow_NN ._. These_DT results_NNS suggest_VBP that_IN a_DT functional_JJ alteration_NN ,_,
          measured_VBN by_IN greater_JJR adherence_NN of_IN cells_NNS under_IN simulated_JJ
          arterial_NN flow_NN conditions_NNS ,_, accompanied_VBD the_DT change_NN in_IN
          cellular_JJ phenotype_NN ,_, following_VBG treatment_NN with_IN
          resveratrol_NN ._.
        
        
          Effect_NN of_IN cell_NN signaling_VBG inhibitors_NNS on_IN cell_NN
          elongation_NN induced_VBN by_IN resveratrol_NN
          Further_RB insights_NNS into_IN the_DT nature_NN of_IN the_DT
          resveratrol-induced_JJ morphologcial_NN changes_NNS came_VBD from_IN
          studies_NNS using_VBG selective_JJ inhibitors_NNS for_IN different_JJ
          signaling_VBG pathways_NNS ._. These_DT include_VBP :_: quin_NN 2_CD -_: AM_NNP
          (_( intracellular_NN [_NN Ca_MD 2_CD +_NN ]_NN )_) ,_, herbimycin_NN A_DT (_( tyrosine_NN kinases_NNS )_) ,_,
          chelerythrine_NN (_( PKC_NNP )_) ,_, cytochalasin_NN D_NNP (_( actin_NN
          microfilaments_NNS )_) ,_, and_CC nocodazole_NN (_( disassembly_RB of_IN
          microtubules_NNS )_) ._. Cells_NNP were_VBD treated_VBN with_IN inhibitors_NNS ,_, at_IN
          concentrations_NNS indicated_VBD in_IN Materials_NNPS and_CC Methods_NNP ,_, and_CC
          then_RB exposed_VBN to_TO resveratrol_NN ._. Representative_NNP confocal_NN
          microscopy_NN fields_NNS for_IN both_DT control_NN and_CC
          resveratrol-treated_JJ cells_NNS were_VBD counted_VBN for_IN elongated_JJ and_CC
          non-elongated_JJ cells_NNS ._. The_DT inhibitors_NNS used_VBN noticeably_RB
          suppressed_VBN cell_NN growth_NN (_( particularly_RB treatment_NN with_IN
          cytochalasin_NN D_NNP and_CC nocodazole_NN )_) ,_, particularly_RB controls_VBZ not_RB
          treated_VBN with_IN resveratrol_NN ._. The_DT degree_NN of_IN growth_NN inhibition_NN
          varied_VBD ,_, depending_VBG on_IN preparations_NNS of_IN primary_JJ BPAEC_NNP ._.
          Interestingly_RB ,_, cells_NNS treated_VBN with_IN resveratrol_NN ,_, which_WDT had_VBD
          to_TO be_VB reduced_VBN to_TO 40_CD h_NN because_IN of_IN adverse_JJ responses_NNS of_IN
          control_NN cells_NNS to_TO inhibitors_NNS (_( see_VB Materials_NNPS and_CC Methods_NNP )_) ,_,
          afforded_VBN better_JJR growth_NN in_IN samples_NNS containing_VBG the_DT
          inhibitors_NNS ._. Table_NNP 1_CD summarized_VBD results_NNS averaged_VBD from_IN 4_CD
          separate_JJ experiments_NNS ,_, each_DT performed_VBN with_IN a_DT different_JJ
          preparation_NN of_IN primary_JJ BPAEC_NNP ._. Since_IN growth_NN of_IN control_NN
          cells_NNS as_RB well_RB as_IN their_PRP$ response_NN to_TO resveratrol_NN and_CC
          addition_NN of_IN inhibitors_NNS differed_VBD between_IN BPAEC_NNP
          preparations_NNS ,_, cells_NNS showing_VBG the_DT elongated_JJ shape_NN in_IN each_DT
          experiment_NN were_VBD calculated_VBN as_IN a_DT percent_NN of_IN total_JJ cells_NNS
          counted_VBN (_( ranging_VBG from_IN 60_CD -_: 700_CD )_) ._. The_DT numbers_NNS obtained_VBN in_IN
          this_DT manner_NN were_VBD used_VBN to_TO calculate_VB the_DT mean_NN (_( %_NN )_) ±_NN SD_NNP ,_, as_IN
          shown_VBN ._. Addition_NNP of_IN chelerythrine_NN ,_, an_DT inhibitor_NN of_IN protein_NN
          kinase_NN C_NNP ,_, caused_VBD a_DT significant_JJ increase_NN in_IN percentage_NN of_IN
          elongated_JJ cells_NNS alone_RB and_CC did_VBD not_RB affect_VB morphologic_JJ
          response_NN of_IN cells_NNS to_TO resveratrol_NN ._. Inhibitors_NNP of_IN
          intracellular_NN [_NN Ca_MD 2_CD +_NN ]_NN and_CC tyrosine_NN kinase_NN activity_NN
          effectively_RB reduced_VBD the_DT percentage_NN of_IN elongated_JJ cells_NNS
          elicited_JJ by_IN resveratrol_NN ._. Results_NNS in_IN Table_NNP 1_CD further_RBR showed_VBD
          that_IN cytoskeletal_NN changes_NNS elicited_JJ by_IN resveratrol_NN also_RB
          appeared_VBD to_TO be_VB linked_VBN to_TO integrity_NN of_IN actin_NN
          microfilaments_NNS and_CC microtubule_NN network_NN as_IN the_DT morphologic_JJ
          changes_NNS were_VBD also_RB substantially_RB lowered_VBD in_IN cells_NNS treated_VBN
          with_IN cytochalasin_NN D_NNP and_CC nocodazole_NN ,_, which_WDT inhibit_VBP
          formation_NN of_IN actin_NN microfilaments_NNS and_CC microtubule_NN
          network_NN ,_, respectively_RB ._.
        
        
          Effect_NN of_IN resveratrol_NN on_IN ERK_NNP 1_CD /_NN 2_CD activation_NN and_CC
          eIF_NN 4_CD E_NNP ,_, eNOS_NN expression_NN
          Biochemical_NNP changes_NNS in_IN resveratrol-treated_JJ BPAEC_NNP were_VBD
          assessed_VBN by_IN western_JJ blot_NN analyses_NNS ._. Fig_NNP ._. 5_LS shows_VBZ that_IN in_IN
          control_NN cells_NNS ,_, level_NN of_IN active_JJ ERK_NNP 1_CD /_NN 2_CD -_: P_NN remained_VBD
          relatively_RB constant_JJ up_IN to_TO 48_CD h_NN but_CC showed_VBD a_DT precipitous_JJ
          decline_NN from_IN 48_CD to_TO 96_CD h_NN (_( panel_NN A_DT )_) ._. Under_IN the_DT same_JJ
          conditions_NNS ,_, levels_NNS of_IN total_JJ ERK_NNP 1_CD /_NN 2_CD (_( panel_NN B_NNP )_) ,_, eIF_NN 4_CD E_NNP
          (_( panel_NN C_NNP )_) ,_, a_DT downstream_JJ effector_NN of_IN ERK_NNP 1_CD /_NN ERK_NNP 2_CD ,_, and_CC actin_NN
          (_( panel_NN E_NNP )_) showed_VBD no_DT substantial_JJ change_NN at_IN all_DT time_NN points_NNS
          assayed_JJ ,_, in_IN control_NN cells_NNS ._. Treatment_NNP with_IN 25_CD μM_NN and_CC 100_CD
          μM_NN resveratrol_NN prevented_VBD the_DT decrease_NN in_IN active_JJ ERK_NNP 1_CD /_NN 2_CD -_: P_NN
          seen_VBN at_IN 96_CD h_NN (_( panel_NN A_DT ,_, last_JJ 3_CD lanes_NNS )_) ._. In_IN addition_NN ,_, these_DT
          concentrations_NNS of_IN resveratrol_NN markedly_RB increased_VBD eNOS_NN
          expression_NN as_RB early_RB as_IN 6_CD -_: h_NN ,_, which_WDT reached_VBD maximum_NN
          induction_NN at_IN 48_CD -_: h_NN ,_, and_CC remained_VBD substantially_RB elevated_VBD at_IN
          96_CD -_: h_NN (_( panel_NN D_NNP )_) ._. Quantification_NNP of_IN relative_JJ changes_NNS of_IN
          total_JJ ERK_NNP 1_CD /_NN 2_CD ,_, active_JJ ERK_NNP 1_CD /_NN 2_CD -_: P_NN ,_, and_CC eNOS_NN as_IN a_DT function_NN of_IN
          time_NN of_IN treatment_NN with_IN two_CD concentrations_NNS of_IN resveratrol_NN
          is_VBZ depicted_VBN in_IN Figure_NN 6_CD ._.
        
      
      
        Discussion_NNP
        
          Modulation_NNP of_IN endothelial_NN cell_NN shape_NN by_IN
          resveratrol_NN
          Size_NN ,_, shape_NN ,_, mutual_JJ orientation_NN ,_, and_CC intercellular_NN
          contacts_NNS in_IN endothelium_NN are_VBP not_RB incidental_JJ and_CC statistic_NN
          events_NNS ,_, but_CC are_VBP precisely_RB and_CC dynamically_RB regulated_VBN ._.
          Reversible_NNP change_NN of_IN endothelial_NN cell_NN shape_NN ,_, mutual_JJ
          orientation_NN of_IN cells_NNS in_IN certain_JJ directions_NNS ,_, changes_NNS in_IN
          intercellular_NN contacts_NNS ,_, are_VBP controlled_VBN by_IN a_DT number_NN of_IN
          factors_NNS ,_, such_JJ as_IN ,_, cooperative_JJ stimulation_NN of_IN the_DT
          receptors_NNS or_CC the_DT systems_NNS of_IN second_JJ messengers_NNS [_NN 32_CD ,_, 33_CD ]_NN ,_,
          dietary_JJ ingredients_NNS ,_, e_SYM ._. g_SYM ._. ,_, retinoids_NNS [_NN 34_CD ]_NN ,_, exercise_NN [_NN
          35_CD ,_, 36_CD ]_NN ,_, and_CC fluid-imposed_JJ shear_NN stress_NN [_NN 37_CD ,_, 38_CD ,_, 39_CD ]_NN ._.
          For_IN example_NN ,_, endothelial_NN cells_NNS are_VBP known_VBN to_TO elongate_VB and_CC
          reorient_NN their_PRP$ cytoskeletons_NNS in_IN the_DT direction_NN of_IN flow_NN as_IN
          a_DT normal_JJ physiological_JJ response_NN to_TO prolonged_JJ shear_NN stress_NN
          [_NN 29_CD ]_NN ._. Results_NNS of_IN the_DT present_JJ studies_NNS show_VBP that_DT treatment_NN
          with_IN resveratrol_NN induces_VBZ a_DT morphologic_JJ change_NN from_IN a_DT
          stellar_JJ to_TO an_DT elongated_JJ shape_NN (_( Figure_NN 1_LS )_) ._. It_PRP is_VBZ tempting_JJ
          to_TO speculate_VB that_DT appearance_NN of_IN such_JJ cellular_JJ phenotype_NN
          involves_VBZ formation_NN of_IN stress_NN fibers_NNS ,_, which_WDT would_MD
          rearrange_VB the_DT cytoskeleton_NN in_IN ways_NNS that_WDT facilitate_VBP better_JJR
          anchoring_VBG of_IN the_DT BPAEC_NNP to_TO the_DT culture_NN substratum_NN and_CC
          contribute_VB to_TO the_DT ability_NN of_IN BPAEC_NNP to_TO resist_VB simulated_JJ
          arterial_NN flow_NN challenge_NN ._. Only_RB studies_VBZ in_IN the_DT future_JJ would_MD
          validate_NN such_JJ a_DT possibility_NN ._. It_PRP is_VBZ also_RB interesting_JJ to_TO
          note_VB that_IN the_DT observed_VBN changes_NNS in_IN resveratrol-treated_JJ
          BPAEC_NNP are_VBP similar_JJ to_TO that_DT described_VBD for_IN EC_NNP subjected_VBN to_TO
          arterial_NN shear_NN ._. We_PRP propose_VBP that_IN this_DT could_MD represent_VB a_DT
          physiologically-relevant_JJ mechanism_NN by_IN which_WDT resveratrol_NN ,_,
          as_IN a_DT polyphenolic_JJ constituent_NN of_IN red_JJ wine_NN ,_, contributes_VBZ to_TO
          cardioprotection_NN by_IN inducing_VBG resistance_NN to_TO potential_JJ
          damage_NN by_IN shearing_VBG forces_NNS ._.
          The_DT mechanism_NN underlying_VBG this_DT cytoskeletal_NN
          rearrangement_NN due_JJ to_TO shear_NN stress_NN is_VBZ ill-defined_JJ ,_, but_CC it_PRP
          has_VBZ been_VBN found_VBN to_TO be_VB linked_VBN to_TO tyrosine_NN kinase_NN activity_NN ,_,
          levels_NNS of_IN intracellular_NN calcium_NN ,_, intact_JJ actin_NN
          microfilaments_NNS ,_, and_CC functional_JJ microtubule_NN network_NN ,_, but_CC
          is_VBZ independent_JJ of_IN protein_NN kinase_NN C_NNP ,_, intermediate_JJ
          filaments_NNS ,_, and_CC stretch-_NN and_CC shear-activated_JJ
          mechanosensitive_JJ K_NNP +_NN channels_NNS [_NN 28_CD ]_NN ._. We_PRP therefore_RB sought_VBD
          to_TO determine_VB whether_IN a_DT similar_JJ mechanism_NN could_MD account_VB
          for_IN the_DT resveratrol-mediated_JJ endothelial_NN shape_NN change_NN ._.
          Our_PRP$ approach_NN involved_VBD using_VBG a_DT number_NN of_IN selective_JJ
          inhibitors_NNS for_IN various_JJ signaling_VBG pathway_NN ._. These_DT studies_NNS
          showed_VBD that_DT quin_NN 2_CD -_: AM_NNP (_( [_NN Ca_MD 2_CD +_NN ]_NN inhibitor_NN )_) ,_, added_VBD together_RB
          with_IN resveratrol_NN ,_, clearly_RB abolished_VBD the_DT endothelial_NN cell_NN
          shape_NN change_NN induced_VBN by_IN the_DT polyphenol_NN ._. In_IN contrast_NN ,_,
          chelerythrine_NN ,_, a_DT PKC_NNP inhibitor_NN ,_, which_WDT added_VBD alone_RB
          triggered_VBN a_DT significant_JJ shape_NN change_NN in_IN BPAEC_NNP ,_, had_VBD no_DT
          effect_NN on_IN resveratrol-elicited_JJ morphological_JJ change_NN
          (_( Table_NNP 1_LS )_) ._. Analyzed_NNP as_IN a_DT whole_NN ,_, these_DT experiments_NNS suggest_VBP
          that_IN the_DT change_NN in_IN cellular_JJ phenotype_NN ,_, as_IN a_DT consequence_NN
          of_IN resveratrol_NN :_: EC_NNP interaction_NN ,_, is_VBZ dependent_JJ on_IN Ca_MD 2_CD +_NN ,_,
          tyrosine_NN kinases_NNS ,_, and_CC intact_JJ actin_NN microfilament_NN and_CC
          microtubules_NNS ._. These_DT results_NNS also_RB raise_VBP the_DT possibility_NN
          that_IN there_EX is_VBZ cellular_JJ heterogeneity_NN within_IN endothelial_NN
          cells_NNS used_VBN in_IN the_DT studies_NNS ,_, based_VBN on_IN the_DT fact_NN that_IN a_DT
          subset_NN displayed_VBD exquisite_JJ sensitivity_NN to_TO chelerythrine_NN ._.
          Overall_RB ,_, these_DT results_NNS support_VBP the_DT notion_NN that_DT
          resveratrol_NN and_CC shear_NN stress_NN induce_VB elongation_NN of_IN the_DT EC_NNP
          cytoskeleton_NN via_IN an_DT overlapping_VBG outside-in_JJ signaling_VBG
          mechanism_NN ._.
          Prolonged_NNP shear_NN stress_NN leading_VBG to_TO mechanotransduction_NN
          signaling_VBG has_VBZ been_VBN shown_VBN to_TO activate_VBP the_DT MAP_NNP kinase_NN
          pathway_NN in_IN EC_NNP ._. Activation_NNP of_IN ERK_NNP 1_CD and_CC ERK_NNP 2_CD ,_, the_DT major_JJ
          components_NNS of_IN the_DT MAPK_NNP pathway_NN ,_, presumably_RB induces_VBZ
          shear-specific_JJ transcription_NN factors_NNS ,_, such_JJ as_IN c-fos_JJ /_NN c-jun_JJ
          and_CC NFκB_NNP ,_, ultimately_RB leading_VBG to_TO changes_NNS in_IN gene_NN
          expression_NN [_NN 30_CD ,_, 31_CD ]_NN ._. Western_JJ blot_NN analysis_NN of_IN control_NN
          and_CC 25_CD μM_NN and_CC 100_CD μM_NN resveratrol-treated_JJ BPAEC_NNP showed_VBD
          that_IN there_EX was_VBD no_DT increase_NN in_IN active_JJ ERK_NNP 1_CD /_NN 2_CD at_IN the_DT 6_CD h_NN
          and_CC 2_CD day_NN time_NN points_NNS ._. Rather_RB ,_, the_DT decline_NN in_IN activated_VBN
          ERK_NNP 1_CD /_NN 2_CD seen_VBN from_IN days_NNS 2_CD to_TO 4_CD of_IN control_NN cells_NNS ,_, was_VBD
          effectively_RB suppressed_VBN by_IN resveratrol_NN ,_, suggesting_VBG that_IN
          the_DT polyphenol_NN may_MD act_VB by_IN affecting_VBG the_DT stability_NN of_IN
          active_JJ ERK_NNP 1_CD /_NN 2_CD (_( Figure_NN 6_CD )_) ._. This_DT may_MD involve_VB modulation_NN of_IN
          MAPK_NNP phosphatase-_NN 1_CD (_( MKP-_NNP 1_LS )_) ,_, a_DT member_NN of_IN the_DT
          immediate-early_JJ response_NN gene_NN product_NN functioning_VBG as_IN a_DT
          dual_JJ specificity_NN phosphase_NN to_TO reverse_VB MAPK_NNP [_NN 40_CD ,_, 41_CD ,_, 42_CD ,_,
          43_CD ,_, 44_CD ]_NN ,_, by_IN resveratrol_NN ._. Previously_RB ,_, it_PRP has_VBZ been_VBN reported_VBN
          that_IN MKP-_NNP 1_CD is_VBZ rapidly_RB induced_VBN in_IN rat_NN carotid_NN arterial_NN
          wall_NN following_VBG balloon_NN catheter_NN injury_NN [_NN 45_CD ]_NN ._. Since_IN no_DT
          noticeable_JJ change_NN in_IN active_JJ ERK_NNP 1_CD /_NN 2_CD occurred_VBD at_IN the_DT 6_CD h_NN or_CC
          2_CD day_NN time_NN points_NNS ,_, where_WRB morphological_JJ changes_NNS clearly_RB
          became_VBD visible_JJ ,_, following_VBG treatment_NN with_IN resveratrol_NN ,_, it_PRP
          seems_VBZ unlikely_JJ that_IN the_DT activation_NN of_IN MAPK_NNP is_VBZ directly_RB
          linked_VBN to_TO the_DT observed_VBD morphologic_JJ changes_NNS ._.
        
        
          Responses_NNS of_IN cultured_JJ endothelial_NN cells_NNS to_TO arterial_NN
          shear_NN stress_NN
          Another_DT significant_JJ contribution_NN of_IN the_DT present_JJ
          research_NN is_VBZ the_DT demonstration_NN that_DT resveratrol_NN promoted_VBD a_DT
          greater_JJR adherence_NN of_IN BPAEC_NNP to_TO the_DT cultured_JJ vehicle_NN 
          in_IN vitro_NN ._. 
          In_IN vivo_NN ,_, such_JJ a_DT cellular_JJ property_NN
          could_MD make_VB endothelial_NN cells_NNS less_RBR likely_JJ to_TO dislodge_NN to_TO
          become_VB part_NN of_IN a_DT growing_VBG thrombotic_JJ plug_NN ._. Restricted_NNP
          detachment_NN could_MD also_RB imply_VB that_IN there_EX is_VBZ less_JJR
          degeneration_NN of_IN the_DT endothelial_NN cell_NN monolayer_NN ,_, which_WDT ,_, in_IN
          turn_NN ,_, would_MD reduce_VB the_DT exposure_NN of_IN the_DT underlying_VBG
          subendothelial_NN matrix_NN components_NNS ,_, thereby_RB making_VBG platelet_NN
          adhesion_NN and_CC aggregation_NN less_RBR likely_JJ ._. The_DT mechanism_NN (_( s_VBZ )_)
          responsible_JJ for_IN the_DT resveratrol-induced_JJ cellular_JJ
          properties_NNS remain_VBP to_TO be_VB further_RBR investigated_VBN ._. One_CD
          possibility_NN centers_NNS on_IN modulation_NN of_IN the_DT number_NN of_IN focal_JJ
          contact_NN adhesion_NN sites_NNS ,_, and_CC /_NN or_CC the_DT effective_JJ
          redistribution_NN of_IN the_DT focal_JJ contacts_NNS ,_, as_RB well_RB as_IN the_DT
          increased_VBN production_NN of_IN the_DT EC-specific_NNP integrin_NN complex_JJ ,_,
          by_IN resveratrol_NN ,_, all_DT of_IN which_WDT could_MD contribute_VB to_TO the_DT
          cardioprotective_JJ mechanism_NN of_IN this_DT polyphenol_NN ._. However_RB ,_,
          it_PRP should_MD be_VB emphasized_VBN that_IN these_DT experiments_NNS involved_VBD
          growing_VBG EC_NNP on_IN plastic_NN ,_, not_RB on_IN layers_NNS of_IN subendothelial_NN
          matrix_NN components_NNS such_JJ as_IN collagen_NN or_CC fibrinogen_NN ._. The_DT
          latter_JJ experimental_JJ format_NN simulating_VBG a_DT more_RBR
          physiologically_RB relevant_JJ subendothelial_NN matrices_NNS may_MD
          yield_VB vastly_RB different_JJ results_NNS ._. These_DT possibilities_NNS
          warrant_VBP further_JJ investigation_NN ._.
        
        
          Induction_NNP of_IN eNOS_NN and_CC modulation_NN of_IN EC_NNP growth_NN by_IN
          resveratrol_NN
          The_DT endothelial_NN cell_NN lining_NN of_IN the_DT blood_NN vessel_NN is_VBZ
          extremely_RB sensitive_JJ to_TO damage_VB from_IN reactive_JJ oxygen_NN
          species_NNS (_( ROS_NNP )_) ,_, the_DT results_NNS of_IN which_WDT are_VBP losses_NNS of_IN both_DT
          microvascular_NN metabolic_JJ function_NN and_CC barrier_NN properties_NNS [_NN
          46_CD ]_NN ._. To_TO minimize_VB such_JJ oxidant_NN damage_NN ,_, cells_NNS rely_VBP on_IN the_DT
          production_NN of_IN nitric_JJ oxide_NN (_( NO_DT )_) by_IN the_DT enzyme_NN nitric_JJ
          oxide_NN synthase_NN (_( eNOS_NN )_) ._. Biological_JJ functions_NNS attributed_VBD to_TO
          NO_DT include_VBP vasodilation_NN [_NN 47_CD ]_NN ,_, inhibition_NN of_IN platelet_NN
          adhesion_NN and_CC aggregation_NN [_NN 48_CD ]_NN ,_, reduction_NN of_IN expression_NN
          of_IN adhesion_NN molecules_NNS and_CC chemokines_NNS [_NN 49_CD ,_, 50_CD ,_, 51_CD ,_, 52_CD ]_NN ,_,
          and_CC suppression_NN of_IN cell_NN growth_NN and_CC migration_NN [_NN 53_CD ,_, 54_CD ]_NN ._.
          Therefore_RB ,_, we_PRP investigated_VBD whether_IN resveratrol_NN treatment_NN
          could_MD lead_VB to_TO increased_VB eNOS_NN expression_NN in_IN endothelial_NN
          cells_NNS ._. We_PRP determined_VBD that_DT resveratrol_NN treatment_NN did_VBD
          induce_VB eNOS_NN expression_NN at_IN all_DT time_NN points_NNS tested_VBN (_( 6_CD h_NN ,_, 2_CD
          days_NNS ,_, and_CC 4_CD days_NNS )_) ._. These_DT results_NNS agreed_VBD with_IN a_DT previous_JJ
          report_NN from_IN this_DT laboratory_NN [_NN 21_CD ]_NN ._. The_DT peak_NN expression_NN of_IN
          eNOS_NN occurred_VBD at_IN 2_CD days_NNS in_IN 100_CD μM_NN resveratrol-treated_JJ
          cells_NNS ._. These_DT findings_NNS could_MD mean_VB that_IN dietary_JJ resveratrol_NN
          is_VBZ capable_JJ of_IN providing_VBG a_DT gradual_JJ yet_RB sustained_VBN increase_NN
          in_IN NO_UH ._. The_DT ability_NN of_IN resveratrol_NN to_TO induce_VB S_NNP /_NN G_NNP 
          2_CD growth_NN arrest_NN [_NN 20_CD ,_, 21_CD ]_NN suggests_VBZ an_DT
          additional_JJ mechanism_NN for_IN cells_NNS to_TO rapidly_RB and_CC efficiently_RB
          repair_VB any_DT endothelial_NN cell_NN damage_NN ._. Overall_RB ,_, the_DT
          collective_JJ effect_NN of_IN resveratrol_NN would_MD be_VB to_TO decrease_VB
          endothelial_NN injury_NN and_CC exposure_NN of_IN the_DT subendothelial_NN
          matrix_NN ,_, which_WDT would_MD lessen_VB the_DT probability_NN of_IN formation_NN
          of_IN atherosclerotic_JJ plaques_NNS and_CC the_DT development_NN of_IN CHD_NNP [_NN
          53_CD ,_, 54_CD ,_, 55_CD ]_NN ._.
        
      
      
        Conclusions_NNP
        Our_PRP$ studies_NNS suggest_VBP that_IN resveratrol_NN interacts_NNS with_IN
        endothelial_NN cells_NNS 
        in_IN vitro_NN to_TO elicit_NN morphological_JJ and_CC
        functional_JJ changes_NNS ._. Specifically_RB ,_, resveratrol_NN induced_VBD an_DT
        elongated_JJ shape_NN ,_, interspersed_VBN with_IN long_JJ ,_, tortuous_JJ
        projections_NNS ,_, in_IN cultured_JJ BPAEC_NNP ._. Treated_NNP cells_NNS resisted_VBD
        detachment_NN from_IN the_DT plastic_NN coverslips_NNS under_IN simulated_JJ
        arterial_NN shear_NN stress_NN conditions_NNS ._. These_DT results_NNS ,_, combined_VBN
        with_IN data_NNS from_IN our_PRP$ previous_JJ studies_NNS ,_, provide_VB additional_JJ
        support_NN for_IN the_DT notion_NN that_IN resveratrol_NN acts_NNS as_IN an_DT
        anti-atherosclerotic_JJ agent_NN ._. Whether_IN these_DT findings_NNS can_MD be_VB
        extrapolated_VBN to_TO humans_NNS require_VBP further_JJ study_NN ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Cell_NNP culture_NN and_CC treatment_NN with_IN resveratrol_NN
          The_DT BPAEC_NNP isolated_VBD from_IN the_DT distal_NN main_JJ intrapulmonary_JJ
          artery_NN of_IN calf_NN lungs_NNS were_VBD cultured_JJ in_IN minimal_JJ essential_JJ
          medium_NN (_( MEM_NNP )_) supplemented_JJ with_IN 15_CD %_NN fetal_JJ bovine_JJ serum_NN and_CC
          containing_VBG D-_NNP valine_NN as_RB previously_RB described_VBD [_NN 56_CD ]_NN ._.
          Plastic_NNP coverslips_NNS on_IN which_WDT the_DT cells_NNS were_VBD cultured_JJ were_VBD
          sterilized_VBN by_IN washing_VBG in_IN ethanol_NN ,_, followed_VBN by_IN rinsing_VBG
          three_CD times_NNS in_IN MEM_NNP and_CC 15_CD min_NN exposure_NN to_TO UV_NNP radiation_NN ._.
          The_DT coverslips_NNS were_VBD placed_VBN in_IN 6_CD -_: well_RB tissue_NN culture_NN
          plates_NNS ,_, and_CC 2_CD ml_NN of_IN the_DT cells_NNS ,_, at_IN an_DT initial_JJ density_NN of_IN 1_CD
          ×_NN 10_CD 5_CD cells_NNS /_NN ml_NN ,_, were_VBD added_VBN to_TO each_DT of_IN the_DT wells_NNS ._.
          Twenty-four_CD h_NN after_IN seeding_VBG ,_, the_DT coverslips_NNS were_VBD treated_VBN
          with_IN 0_CD ,_, 10_CD ,_, 25_CD ,_, 50_CD ,_, and_CC 100_CD μM_NN resveratrol_NN and_CC maintained_VBN
          for_IN 2_CD days_NNS at_IN 37_CD °_NN C_NNP until_IN they_PRP were_VBD fixed_VBN and_CC stained_JJ for_IN
          confocal_NN microscopy_NN ._.
        
        
          Preparation_NNP and_CC staining_VBG of_IN slides_NNS
          Coverslips_NNP containing_VBG adhered_VBD BPAEC_NNP were_VBD washed_VBN for_IN 5_CD
          min_NN in_IN TBS_NNP ,_, fixed_VBN with_IN 5_CD %_NN glutaraldehyde_NN in_IN 0_CD ._. 1_CD M_NNP
          cacodylate_NN (_( pH_NN 7_CD ._. 4_LS )_) for_IN 15_CD min_NN ,_, washed_VBD again_RB for_IN 5_CD min_NN in_IN
          TBS_NNP ,_, then_RB stored_VBD in_IN 0_CD ._. 1_CD M_NNP cacodylate_NN /_NN 7_CD %_NN sucrose_NN at_IN 4_CD °_NN C_NNP
          until_IN staining_VBG ._. Cells_NNP were_VBD permeabilized_JJ with_IN 0_CD ._. 1_CD %_NN Triton_NNP
          X-_NNP 100_CD /_NN TBS_NNP for_IN 3_CD min_NN ,_, washed_VBD twice_RB with_IN TBS_NNP ,_, blocked_VBD twice_RB
          for_IN 3_CD min_NN with_IN 0_CD ._. 1_CD %_NN bovine_JJ serum_NN albumin_NN in_IN TBS_NNP ,_, and_CC
          incubated_JJ with_IN rhodamine-conjugated_JJ phalloidin_NN for_IN 20_CD
          min_NN ._. Routinely_NNP ,_, 5_CD μl_NN of_IN rhodamine-phalloidin_JJ ,_, dissolved_VBN
          in_IN 200_CD μl_NN TBS_NNP ,_, was_VBD used_VBN for_IN each_DT coverslip_NN stained_JJ ._. The_DT
          coverslips_NNS were_VBD wash_VB with_IN 0_CD ._. 1_CD %_NN BSA_NNP /_NN TBS_NNP for_IN 3_CD min_NN ,_, then_RB
          mounted_VBD in_IN an_DT inverted_JJ position_NN onto_IN TBS-containing_NNP
          beveled_JJ glass_NN slides_NNS and_CC sealed_VBN with_IN clear_JJ nail_NN
          polish_NN ._.
        
        
          Perfusion_NNP
          A_DT parallel_JJ plate_NN perfusion_NN chamber_NN as_IN described_VBN
          previously_RB [_NN 57_CD ]_NN was_VBD used_VBN to_TO generate_VB simulated_JJ arterial_NN
          flow_NN conditions_NNS ._. The_DT chamber_NN consisted_VBD of_IN three_CD pieces_NNS :_:
          two_CD rectangular_JJ slabs_NNS and_CC a_DT central_JJ knob_NN with_IN a_DT
          depression_NN that_WDT fits_VBZ 18_CD by_IN 21_CD mm_NN coverslips_NNS ._. The_DT
          depression_NN containing_VBG the_DT coverslip_NN was_VBD placed_VBN
          perpendicularly_RB to_TO the_DT flow_NN of_IN perfusate_NN ._. A_DT laminar_NN
          arterial_NN shear_NN rate_NN of_IN 650_CD s_VBZ -_: 1_CD was_VBD achieved_VBN based_VBN on_IN the_DT
          dimensions_NNS of_IN the_DT flow_NN chamber_NN slit_NN and_CC a_DT constant_JJ flow_NN
          rate_NN of_IN 10_CD ml_NN /_NN min_NN ._. After_IN preincubation_NN at_IN 37_CD °_NN C_NNP ,_, minimal_JJ
          medium_NN was_VBD drawn_VBN directly_RB by_IN an_DT eight_CD roller_NN peristaltic_JJ
          pump_NN through_IN the_DT perfusion_NN chamber_NN containing_VBG the_DT
          BPAEC-covered_NNP coverslip_NN positioned_VBD 70_CD mm_NN from_IN the_DT inlet_NN
          valve_NN at_IN a_DT rate_NN of_IN 10_CD ml_NN /_NN min_NN for_IN either_DT 2_CD min_NN or_CC 5_CD min_NN ._. A_DT
          recirculating_VBG system_NN was_VBD employed_VBN to_TO recycle_VB the_DT medium_NN
          after_IN passing_VBG through_IN the_DT chamber_NN ._.
        
        
          Confocal_NNP microscopy_NN
          Prepared_JJ slides_NNS containing_VBG adhered_VBD BPAEC_NNP were_VBD examined_VBN
          using_VBG a_DT BioRad_NNP confocal_NN microscope_NN ._. The_DT cells_NNS were_VBD imaged_JJ
          following_NN excitation_NN of_IN rhodamine-phalloidin_JJ with_IN an_DT
          argon_NN laser_NN beam_NN at_IN a_DT wavelength_NN of_IN 554_CD nm_NN using_VBG either_CC
          an_DT inverted-_NN or_CC an_DT uprighted-staged_JJ microscope_NN equipped_VBN
          with_IN either_DT a_DT 10_CD X_NNP or_CC a_DT 20_CD X_NNP oil-free_JJ objective_NN and_CC an_DT
          epifluorescent_NN illumination_NN attachment_NN ._. Cells_NNP viewed_VBD in_IN
          representative_NN field_NN screen_NN captures_NNS were_VBD counted_VBN
          manually_RB for_IN cell_NN morphology_NN and_CC classified_VBN as_IN either_DT
          normal_JJ or_CC elongated_JJ ._.
        
        
          Inhibitor_NNP study_NN
          Passages_NNP 4_CD -_: 5_CD BPAEC_NNP were_VBD seeded_VBN on_IN plastic_NN coverslips_NNS
          as_IN described_VBN above_IN ._. Inhibitor_NNP concentrations_NNS were_VBD the_DT
          same_JJ as_IN in_IN [_NN 28_CD ]_NN ._. Stock_NN solutions_NNS were_VBD prepared_VBN by_IN
          dissolving_VBG the_DT inhibitors_NNS in_IN DMSO_NNP ._. The_DT inhibitors_NNS used_VBN
          and_CC their_PRP$ stock_NN solutions_NNS were_VBD as_IN follows_VBZ :_: quin_NN 2_CD -_: AM_NNP
          (_( Sigma_NNP ,_, 2_CD mM_NN )_) ,_, herbimycin_NN A_DT (_( GibcoBRL_NNP ,_, 0_CD ._. 175_CD mM_NN )_) ,_,
          chelerythrine_NN (_( Sigma_NNP ,_, 0_CD ._. 4_CD mM_NN )_) ,_, cytochalasin_NN D_NNP (_( Sigma_NNP ,_, 8_CD
          μM_NN )_) ,_, nocodazole_NN (_( Sigma_NNP ,_, 0_CD ._. 66_CD mM_NN )_) ._. Quin_NNP 2_CD -_: AM_NNP ,_, herbimycin_NN A_DT ,_,
          chelerythrine_NN ,_, and_CC cytochalasin_NN D_NNP were_VBD stored_VBN at_IN -_: 20_CD °_NN C_NNP ,_,
          and_CC nocodazole_NN was_VBD stored_VBN at_IN 4_CD °_NN C_NNP ._. The_DT stock_NN solutions_NNS
          were_VBD diluted_VBN 1_CD :_: 200_CD in_IN MEM_NNP to_TO give_VB the_DT following_VBG final_JJ
          concentrations_NNS :_: quin_NN 2_CD -_: AM_NNP (_( 10_CD μM_NN )_) ,_, herbimycin_NN A_DT (_( 875_CD nM_NN )_) ,_,
          chelerythrine_NN (_( 2_CD μM_NN )_) ,_, cytochalasin_NN D_NNP (_( 40_CD nM_NN )_) ,_, nocodazole_NN
          (_( 3_CD ._. 3_LS μM_NN )_) ._. Inhibitors_NNP were_VBD applied_VBN 24_CD h_NN prior_RB to_TO the_DT
          addition_NN of_IN resveratrol_NN ,_, except_IN for_IN quin_NN 2_CD -_: AM_NNP ,_, which_WDT was_VBD
          applied_VBN 1_CD h_NN prior_RB to_TO resveratrol_NN treatment_NN ._. Since_IN cells_NNS
          treated_VBN with_IN various_JJ inhibitors_NNS grew_VBD less_RBR well_RB ,_, compared_VBN
          to_TO controls_NNS ,_, treatment_NN with_IN 100_CD μM_NN resveratrol_NN was_VBD
          reduced_VBN to_TO approximately_RB 40_CD h_NN ._. Fixing_NNP and_CC staining_VBG of_IN
          cells_NNS for_IN confocal_NN microscopy_NN was_VBD as_IN described_VBN above_IN ._.
        
        
          Western_JJ blot_NN analysis_NN
          Control_NNP and_CC treated_VBN cells_NNS were_VBD lysed_JJ by_IN repeated_VBN
          freeze-thaw_JJ cycles_NNS with_IN buffer_NN containing_VBG 10_CD mM_NN HEPES_NNP (_( pH_NN
          7_CD ._. 5_LS )_) ,_, 1_CD ._. 5_CD mM_NN Mg_NNP (_( OAc_NNP )_) 
          2_CD ,_, 1_CD mM_NN dithiothreitol_NN (_( DTT_NNP )_) ,_, 0_CD ._. 5_CD %_NN
          NP_NNP 40_CD ,_, 5_CD %_NN glycerol_NN ,_, 0_CD ._. 5_CD mM_NN phenylmethylsulfonyl_NN fluoride_NN ,_,
          and_CC 10_CD μg_NN /_NN ml_NN each_DT of_IN the_DT protease_NN inhibitors_NNS aprotinin_NN ,_,
          pepstatin_NN ,_, and_CC leupeptin_NN ._. Cell-free_NNP extracts_NNS were_VBD
          obtained_VBN by_IN centrifugation_NN in_IN a_DT microcentrifuge_NN ._. Lysates_NNP
          (_( 7_CD -_: 10_CD μg_NN )_) from_IN control_NN and_CC treated_VBN cells_NNS were_VBD separated_JJ
          on_IN 10_CD %_NN SDS-PAGE_NNP ._. The_DT separated_JJ proteins_NNS were_VBD transferred_VBN
          to_TO nitrocellulose_NN membranes_NNS ,_, and_CC the_DT membranes_NNS were_VBD
          incubated_JJ with_IN the_DT respective_JJ primary_JJ and_CC secondary_JJ
          antibodies_NNS ._. The_DT monoclonal_NN primary_JJ antibodies_NNS used_VBN and_CC
          their_PRP$ dilutions_NNS were_VBD as_IN follows_VBZ :_: Phosphorylated_NNP ,_, active_JJ
          ERK_NNP 1_CD /_NN 2_CD -_: P_NN (_( RBI_NNP /_NN Sigma_NNP ,_, 1_CD :_: 1000_CD )_) ,_, total_JJ ERK_NNP 1_CD /_NN 2_CD (_( RBI_NNP /_NN Sigma_NNP ,_,
          1_CD :_: 1000_CD )_) ,_, eIF_NN 4_CD E_NNP (_( Santa_NNP Cruz_NNP ,_, 1_CD :_: 250_CD )_) ,_, eNOS_NN (_( Sigma_NNP 1_CD :_: 1000_CD )_) ._.
          Membranes_NNP were_VBD probed_JJ with_IN alkaline_NN
          phosphatase-conjugated_JJ IgG_NNP (_( Santa_NNP Cruz_NNP ,_, 1_CD :_: 1500_CD )_) or_CC
          horseradish_NN peroxidase-conjugated_JJ IgG_NNP (_( Santa_NNP Cruz_NNP ,_,
          1_CD :_: 2000_CD )_) ._. Specific_JJ immunoreactive_JJ bands_NNS were_VBD identified_VBN by_IN
          color_NN reaction_NN or_CC enhanced_JJ chemiluminescence_NN ,_,
          respectively_RB ._.
        
      
    
  
